Utility of the aged BALB/c mouse model to demonstrate prevention and control strategies for severe acute respiratory syndrome coronavirus (SARS-CoV).
Identifieur interne : 001C38 ( PubMed/Checkpoint ); précédent : 001C37; suivant : 001C39Utility of the aged BALB/c mouse model to demonstrate prevention and control strategies for severe acute respiratory syndrome coronavirus (SARS-CoV).
Auteurs : Leatrice N. Vogel [États-Unis] ; Anjeanette Roberts ; Christopher D. Paddock ; Gillian L. Genrich ; Elaine W. Lamirande ; Sagar U. Kapadia ; John K. Rose ; Sherif R. Zaki ; Kanta SubbaraoSource :
- Vaccine [ 0264-410X ] ; 2007.
Descripteurs français
- KwdFr :
- Animaux, Antibioprophylaxie (), Anticorps antiviraux (immunologie), Immunisation (), Modèles animaux, Résultat thérapeutique, Souris, Souris de lignée BALB C, Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (immunologie), Syndrome respiratoire aigu sévère (virologie), Vaccination (), Vaccins antiviraux (immunologie), Virus du SRAS (immunologie).
- MESH :
- immunologie : Anticorps antiviraux, Syndrome respiratoire aigu sévère, Vaccins antiviraux, Virus du SRAS.
- virologie : Syndrome respiratoire aigu sévère.
- Animaux, Antibioprophylaxie, Immunisation, Modèles animaux, Résultat thérapeutique, Souris, Souris de lignée BALB C, Syndrome respiratoire aigu sévère, Vaccination.
English descriptors
- KwdEn :
- Animals, Antibiotic Prophylaxis (methods), Antibodies, Viral (immunology), Immunization (methods), Mice, Mice, Inbred BALB C, Models, Animal, SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (prevention & control), Severe Acute Respiratory Syndrome (virology), Treatment Outcome, Vaccination (methods), Viral Vaccines (immunology).
- MESH :
- chemical , immunology : Antibodies, Viral, Viral Vaccines.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome.
- methods : Antibiotic Prophylaxis, Immunization, Vaccination.
- prevention & control : Severe Acute Respiratory Syndrome.
- virology : Severe Acute Respiratory Syndrome.
- Animals, Mice, Mice, Inbred BALB C, Models, Animal, Treatment Outcome.
Abstract
The causative agent of Severe Acute Respiratory Syndrome (SARS) was identified as a coronavirus (CoV) following the outbreak of 2002-2003. There are currently no licensed vaccines or treatments for SARS-CoV infections. Potential prevention and control strategies that show promise in vitro must be evaluated in animal models. The aged BALB/c mouse model for SARS supports a high level of viral replication in association with clinical illness and disease that mimics SARS in the elderly. We tested two preventive strategies, vaccination and passive transfer of serum antibody, to determine the extent of protection achieved against SARS-CoV challenge in this model. These approaches were able to achieve or induce antibody titers sufficient to reduce viral load, protect from weight loss and reduce or eliminate histopathologic changes in the lungs of aged mice. This study validates the utility of the aged BALB/c mouse model for evaluation of the efficacy of vaccines and immunoprophylaxis.
DOI: 10.1016/j.vaccine.2006.11.055
PubMed: 17227689
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:17227689Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Utility of the aged BALB/c mouse model to demonstrate prevention and control strategies for severe acute respiratory syndrome coronavirus (SARS-CoV).</title><author><name sortKey="Vogel, Leatrice N" sort="Vogel, Leatrice N" uniqKey="Vogel L" first="Leatrice N" last="Vogel">Leatrice N. Vogel</name><affiliation wicri:level="2"><nlm:affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Roberts, Anjeanette" sort="Roberts, Anjeanette" uniqKey="Roberts A" first="Anjeanette" last="Roberts">Anjeanette Roberts</name></author><author><name sortKey="Paddock, Christopher D" sort="Paddock, Christopher D" uniqKey="Paddock C" first="Christopher D" last="Paddock">Christopher D. Paddock</name></author><author><name sortKey="Genrich, Gillian L" sort="Genrich, Gillian L" uniqKey="Genrich G" first="Gillian L" last="Genrich">Gillian L. Genrich</name></author><author><name sortKey="Lamirande, Elaine W" sort="Lamirande, Elaine W" uniqKey="Lamirande E" first="Elaine W" last="Lamirande">Elaine W. Lamirande</name></author><author><name sortKey="Kapadia, Sagar U" sort="Kapadia, Sagar U" uniqKey="Kapadia S" first="Sagar U" last="Kapadia">Sagar U. Kapadia</name></author><author><name sortKey="Rose, John K" sort="Rose, John K" uniqKey="Rose J" first="John K" last="Rose">John K. Rose</name></author><author><name sortKey="Zaki, Sherif R" sort="Zaki, Sherif R" uniqKey="Zaki S" first="Sherif R" last="Zaki">Sherif R. Zaki</name></author><author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="RBID">pubmed:17227689</idno><idno type="pmid">17227689</idno><idno type="doi">10.1016/j.vaccine.2006.11.055</idno><idno type="wicri:Area/PubMed/Corpus">001F23</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001F23</idno><idno type="wicri:Area/PubMed/Curation">001F23</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001F23</idno><idno type="wicri:Area/PubMed/Checkpoint">001C38</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001C38</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Utility of the aged BALB/c mouse model to demonstrate prevention and control strategies for severe acute respiratory syndrome coronavirus (SARS-CoV).</title><author><name sortKey="Vogel, Leatrice N" sort="Vogel, Leatrice N" uniqKey="Vogel L" first="Leatrice N" last="Vogel">Leatrice N. Vogel</name><affiliation wicri:level="2"><nlm:affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Roberts, Anjeanette" sort="Roberts, Anjeanette" uniqKey="Roberts A" first="Anjeanette" last="Roberts">Anjeanette Roberts</name></author><author><name sortKey="Paddock, Christopher D" sort="Paddock, Christopher D" uniqKey="Paddock C" first="Christopher D" last="Paddock">Christopher D. Paddock</name></author><author><name sortKey="Genrich, Gillian L" sort="Genrich, Gillian L" uniqKey="Genrich G" first="Gillian L" last="Genrich">Gillian L. Genrich</name></author><author><name sortKey="Lamirande, Elaine W" sort="Lamirande, Elaine W" uniqKey="Lamirande E" first="Elaine W" last="Lamirande">Elaine W. Lamirande</name></author><author><name sortKey="Kapadia, Sagar U" sort="Kapadia, Sagar U" uniqKey="Kapadia S" first="Sagar U" last="Kapadia">Sagar U. Kapadia</name></author><author><name sortKey="Rose, John K" sort="Rose, John K" uniqKey="Rose J" first="John K" last="Rose">John K. Rose</name></author><author><name sortKey="Zaki, Sherif R" sort="Zaki, Sherif R" uniqKey="Zaki S" first="Sherif R" last="Zaki">Sherif R. Zaki</name></author><author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name></author></analytic><series><title level="j">Vaccine</title><idno type="ISSN">0264-410X</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibiotic Prophylaxis (methods)</term><term>Antibodies, Viral (immunology)</term><term>Immunization (methods)</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Models, Animal</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>Treatment Outcome</term><term>Vaccination (methods)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Antibioprophylaxie ()</term><term>Anticorps antiviraux (immunologie)</term><term>Immunisation ()</term><term>Modèles animaux</term><term>Résultat thérapeutique</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Syndrome respiratoire aigu sévère ()</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Syndrome respiratoire aigu sévère (virologie)</term><term>Vaccination ()</term><term>Vaccins antiviraux (immunologie)</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term><term>Syndrome respiratoire aigu sévère</term><term>Vaccins antiviraux</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Antibiotic Prophylaxis</term><term>Immunization</term><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Models, Animal</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Antibioprophylaxie</term><term>Immunisation</term><term>Modèles animaux</term><term>Résultat thérapeutique</term><term>Souris</term><term>Souris de lignée BALB C</term><term>Syndrome respiratoire aigu sévère</term><term>Vaccination</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The causative agent of Severe Acute Respiratory Syndrome (SARS) was identified as a coronavirus (CoV) following the outbreak of 2002-2003. There are currently no licensed vaccines or treatments for SARS-CoV infections. Potential prevention and control strategies that show promise in vitro must be evaluated in animal models. The aged BALB/c mouse model for SARS supports a high level of viral replication in association with clinical illness and disease that mimics SARS in the elderly. We tested two preventive strategies, vaccination and passive transfer of serum antibody, to determine the extent of protection achieved against SARS-CoV challenge in this model. These approaches were able to achieve or induce antibody titers sufficient to reduce viral load, protect from weight loss and reduce or eliminate histopathologic changes in the lungs of aged mice. This study validates the utility of the aged BALB/c mouse model for evaluation of the efficacy of vaccines and immunoprophylaxis.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17227689</PMID><DateCompleted><Year>2007</Year><Month>08</Month><Day>15</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0264-410X</ISSN><JournalIssue CitedMedium="Print"><Volume>25</Volume><Issue>12</Issue><PubDate><Year>2007</Year><Month>Mar</Month><Day>08</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Utility of the aged BALB/c mouse model to demonstrate prevention and control strategies for severe acute respiratory syndrome coronavirus (SARS-CoV).</ArticleTitle><Pagination><MedlinePgn>2173-9</MedlinePgn></Pagination><Abstract><AbstractText>The causative agent of Severe Acute Respiratory Syndrome (SARS) was identified as a coronavirus (CoV) following the outbreak of 2002-2003. There are currently no licensed vaccines or treatments for SARS-CoV infections. Potential prevention and control strategies that show promise in vitro must be evaluated in animal models. The aged BALB/c mouse model for SARS supports a high level of viral replication in association with clinical illness and disease that mimics SARS in the elderly. We tested two preventive strategies, vaccination and passive transfer of serum antibody, to determine the extent of protection achieved against SARS-CoV challenge in this model. These approaches were able to achieve or induce antibody titers sufficient to reduce viral load, protect from weight loss and reduce or eliminate histopathologic changes in the lungs of aged mice. This study validates the utility of the aged BALB/c mouse model for evaluation of the efficacy of vaccines and immunoprophylaxis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vogel</LastName><ForeName>Leatrice N</ForeName><Initials>LN</Initials><AffiliationInfo><Affiliation>Laboratory of Infectious Diseases, NIAID, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Anjeanette</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Paddock</LastName><ForeName>Christopher D</ForeName><Initials>CD</Initials></Author><Author ValidYN="Y"><LastName>Genrich</LastName><ForeName>Gillian L</ForeName><Initials>GL</Initials></Author><Author ValidYN="Y"><LastName>Lamirande</LastName><ForeName>Elaine W</ForeName><Initials>EW</Initials></Author><Author ValidYN="Y"><LastName>Kapadia</LastName><ForeName>Sagar U</ForeName><Initials>SU</Initials></Author><Author ValidYN="Y"><LastName>Rose</LastName><ForeName>John K</ForeName><Initials>JK</Initials></Author><Author ValidYN="Y"><LastName>Zaki</LastName><ForeName>Sherif R</ForeName><Initials>SR</Initials></Author><Author ValidYN="Y"><LastName>Subbarao</LastName><ForeName>Kanta</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U54 AI057158</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AI057158</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>Z01 AI000934-03</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>12</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019072" MajorTopicYN="N">Antibiotic Prophylaxis</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D023421" MajorTopicYN="N">Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>09</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>1</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>1</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17227689</ArticleId><ArticleId IdType="pii">S0264-410X(06)01251-5</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2006.11.055</ArticleId><ArticleId IdType="pmc">PMC1847333</ArticleId><ArticleId IdType="mid">NIHMS19191</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Science. 2003 Oct 10;302(5643):276-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12958366</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Infect Dis. 2003 Sep;9(9):1064-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14519241</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 2005 Feb 15;191(4):507-14</Citation><ArticleIdList><ArticleId IdType="pubmed">15655773</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect Dis. 2006 Mar 1;193(5):685-92</Citation><ArticleIdList><ArticleId IdType="pubmed">16453264</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2002 Aug;76(15):7506-17</Citation><ArticleIdList><ArticleId IdType="pubmed">12097563</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 Apr;78(7):3572-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15016880</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Thorax. 2003 Aug;58(8):686-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12885985</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Trends Microbiol. 2006 Jul;14(7):299-303</Citation><ArticleIdList><ArticleId IdType="pubmed">16759866</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2002 Mar;76(6):2730-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11861840</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation><ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2005 Sep 30;340(2):174-82</Citation><ArticleIdList><ArticleId IdType="pubmed">16043204</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Rev Immunol. 2006 Mar;6(3):231-43</Citation><ArticleIdList><ArticleId IdType="pubmed">16498452</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14040-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16169905</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2005 May;79(9):5833-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15827197</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Maryland</li></region></list><tree><noCountry><name sortKey="Genrich, Gillian L" sort="Genrich, Gillian L" uniqKey="Genrich G" first="Gillian L" last="Genrich">Gillian L. Genrich</name><name sortKey="Kapadia, Sagar U" sort="Kapadia, Sagar U" uniqKey="Kapadia S" first="Sagar U" last="Kapadia">Sagar U. Kapadia</name><name sortKey="Lamirande, Elaine W" sort="Lamirande, Elaine W" uniqKey="Lamirande E" first="Elaine W" last="Lamirande">Elaine W. Lamirande</name><name sortKey="Paddock, Christopher D" sort="Paddock, Christopher D" uniqKey="Paddock C" first="Christopher D" last="Paddock">Christopher D. Paddock</name><name sortKey="Roberts, Anjeanette" sort="Roberts, Anjeanette" uniqKey="Roberts A" first="Anjeanette" last="Roberts">Anjeanette Roberts</name><name sortKey="Rose, John K" sort="Rose, John K" uniqKey="Rose J" first="John K" last="Rose">John K. Rose</name><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name><name sortKey="Zaki, Sherif R" sort="Zaki, Sherif R" uniqKey="Zaki S" first="Sherif R" last="Zaki">Sherif R. Zaki</name></noCountry><country name="États-Unis"><region name="Maryland"><name sortKey="Vogel, Leatrice N" sort="Vogel, Leatrice N" uniqKey="Vogel L" first="Leatrice N" last="Vogel">Leatrice N. Vogel</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C38 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001C38 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:17227689
|texte= Utility of the aged BALB/c mouse model to demonstrate prevention and control strategies for severe acute respiratory syndrome coronavirus (SARS-CoV).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:17227689" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |